The behavioral neurologist at NYU Langone Health and chief medical officer at Isaac Health shared his reaction to the recent approval of donanemab for patients with Alzheimer disease. [WATCH TIME: 7 minutes]:
Source: Neurology Read More
Newly Approved Donanemab Brings Another Treatment Option for Alzheimer Disease: Joel Salinas, MD, MBA
Related Posts
<![CDATA[Votoplam Shows Dose-Dependent Slowing of
Disease Progression in Stage 2 Huntington Disease]]>
<![CDATA[Votoplam Shows Dose-Dependent Slowing of Disease Progression in Stage 2 Huntington Disease]]>
